Addition of Propolis to Irinotecan Therapy Prolongs Survival
in Ehrlich Ascites Tumor-Bearing Mice
Online Ahead of Print: January 2, 2014
We investigated possible synergistic action of anticancer
drug Irinotecan (IRI) combined with ethanolic (EEP) and water-soluble (WSDP)
derivate of propolis on Swiss albino mice injected with Ehrlich ascites tumor
(EAT). For survival analysis mice were administered WSDP and EEP (100 mg/kg)
daily for 3 consecutive days, beginning on 3rd day after EAT cell (1×106)
injection. IRI was administered at a dose of 50 mg/kg on days 1, 13, and 19. We
simultaneously studied peripheral white blood cell count, cell types washed
from the peritoneal cavity, functional activity of macrophages from peritoneal
cavity, and the level of primary DNA damage in leukocytes, kidney, and liver
cells using the alkaline comet assay. Three out of 9 mice per group survived
the entire duration of the experiment (90 days) in groups treated with IRI
combined with WSDP and EEP. All test components increased survival of mice by
7.53% to 231.54%. Combined treatment with IRI and/or WSDP and EEP significantly
decreased percentage of tumor cells in the peritoneal cavity as compared to
nontreated EAT-injected mice. All treated animals had significantly higher
percentage of neutrophils in the peritoneal cavity in comparison to nontreated
EAT-injected mice. We observed significantly higher value of DNA damage in
leukocytes of mice treated with IRI and combination of IRI and/or WSDP and EEP
as compared to nontreated EAT-injected mice, while the same treatment decreased
DNA damage in kidney.
Our results showed that addition of propolis to IRI
treatment enhanced antitumor activity of IRI and prolongs survival in
EAT-bearing mice, which definitely deserve further studies to clarify the
possible mechanisms of antitumor actions of combined herb–drug treatments.
No comments:
Post a Comment